



## NAVANA PHARMACEUTICALS PLC.

99 Gulshan Avenue, Rupayan Golden Age, 6<sup>th</sup> Floor, Plot-6, Block-CWN(C), Dhaka-1212.  
www.navanapharma.com, Phone: 01321131154

### PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of **Navana Pharmaceuticals PLC.** and stakeholders that the Board of Directors of the company in its 61st meeting held on Tuesday, 28<sup>th</sup> October, 2025 ended at 4.00 p.m. at its Corporate office at 99 Gulshan Avenue, Rupayan Golden Age, 6<sup>th</sup> Floor, Plot-6, Block-CWN(C), Dhaka-1212, has considered and approved, among others, the Audited Financial Statement for the year ended on June 30, 2025 and took the following Price Sensitive Decisions: -

#### a. Information Relating 39<sup>th</sup> Annual General Meeting (AGM):

❖ Recommended Dividend : **14 % Cash only for general shareholders** (Sponsor shareholders & Directors and few shareholders who hold significant share of the company will not receive any dividend)

Total Paid-up share **107,416,217**, Director & Sponsor are hold **33,989,714** nos. shares & **39,480,432** nos. share are hold other shareholder who are willingly forgo their dividend along with Director & Sponsor for the betterment of the company. Whereas **BDT 47,524,499.40** payable to the General Shareholders as 14% cash dividend.

- ❖ Record Date : Wednesday, November 19, 2025
- ❖ Date of the 39th AGM : December 31, 2025
- ❖ Mode of the 39th AGM : Hybrid
- ❖ Venue of hybrid AGM : Green Hall, Jolshiri Golf Club, Jolshiri Abashon, Sector-17, Rupganj, Narayanganj.
- ❖ Time of hybrid AGM : 3.00 PM
- ❖ Virtual Link of hybrid AGM : Will be notified later on due course.

#### b. The key comparative financial disclosure on Audited Financial Statement for the year ended on June 30, 2025 as follows:

Sl. No.	Particulars	2024-2025	2023-2024
I.	Earnings per Share (EPS)	4.54	3.77
		4.50 (Diluted)	
II.	Net Asset Value (BDT in Million)	4,864.92	4,561.10
III.	Net Asset Value per Share (NAV)(BDT)	45.29	42.46
IV.	Net Operating Cash Flow per Share (NOCFPS) (BDT)	16.90	6.58

#### c. Explanatory notes for the significant variation in the Financial Statements for the year ended June 30, 2025:

##### Issue-1: Earnings per Share (EPS):

Gross profit and Net profit after tax increased due to higher of Net sales & efficient uses of raw materials. As a result, Earnings per Share (EPS) increased to Tk. 4.54 from TK. 3.77 for the reporting period.

##### Issue-2: Net Operating Cash Flow per Share (NOCFPS):

Net Operating Cash Flow per Share (NOCFPS) has increased to Tk. 16.90 from Tk. 6.58, due to cash received from customer was higher than the cash payment to the vendors.

#### Notes:

- ❖ The shareholders whose name will appear in the Depository Register (CDBL) or register folio the member of the company on the "**Record Date**" i.e. **19 November 2025** will be entitled to attend in the Annual General Meeting and to receive the dividend.
- ❖ Members are requested to update their Bank Account Number, Taxpayer's Identification Numbers (e-TIN), Address, E-mail address and cell no before the record date to their respective depository participant.
- ❖ The concerned brokerage houses & merchant bankers are requested to provide us with a statement with the details (shareholders name, BOID number, e-TIN number, gross dividend receivable, applicable tax rate, and net dividend receivable) of their margin loan holders who hold shares of the Company as on the Record Date, along with the name of the contact person in this connection. The brokerage houses & merchant bankers are also requested to provide us with their Bank Account Name, Number, Routing number etc. on or before 10 December 2025.
- ❖ In compliance with Listing Regulation 2015 of Dhaka Stock Exchange PLC. and Chittagong Stock Exchange PLC., the company will publish the details Annual Audited Financial Statement in its website (www.navanapharma.com).

On behalf of the Company  
Sd/-

**Lorens Shamol Mollick FCS**  
Company Secretary

Dated: October 28, 2025